Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRTN3 | P24158 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | ECE1 | P42892 | 5/20 | 0.40 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2939235 | 0.90 | PRTN3 (0.46) | PRTN3ELANESIRT2SIRT1HSD17B10 | |
| SCHEMBL4710021 | 0.84 | PRTN3 (0.44) | PRTN3ELANEHSD17B10 | |
| SCHEMBL6130863 | 0.84 | ECE1 (0.37) | PRTN3ELANEECE1MME | |
| SCHEMBL2355898 | 0.81 | SYK (0.47) | PRTN3ELANEECE1MME | |
| SCHEMBL2940083 | 0.78 | KCNB1 (0.33) | PPARG | |
| SCHEMBL2350988 | 0.76 | ELANE (0.52) | PRTN3ELANEECE1MME | |
| SCHEMBL2353547 | 0.75 | ELANE (0.60) | PRTN3ELANEECE1MMEHSD17B10 | |
| SCHEMBL6130870 | 0.74 | ALDH1A1 (0.33) | PPARG | |
| SCHEMBL2353359 | 0.73 | ELANE (0.48) | PRTN3ELANEHSD17B10 | |
| SCHEMBL2350438 | 0.73 | ELANE (0.50) | PRTN3ELANEECE1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4472997-B2 | — | — | 2010-06-02 | — | — | JP | claimed |
| EP-1874322-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-09 | — | — | EP | claimed |
| EP-1817041-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006113247-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | WO | claimed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | claimed |
| JP-2006504622-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | claimed |
| EP-1874322-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1817041-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006113247-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |